Stocks Health care VRCA
NASDAQ · Health careVerrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. brought in $30.3M of revenue over the twelve months to June 30, 2026, up 106.2% from a year earlier. It posted a net loss of $31.2M. In fiscal 2025 capital spending exceeded operating cash flow by $17.6M. At June 30, 2026 it held $11.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Verrica Pharmaceuticals Inc.
- Net worth
- Verrica Pharmaceuticals Inc. has a market value (market cap) of $61.7M at the latest share price, and shareholders' equity of $4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $35.6M (+370.2% year on year), with a net loss of $17.9M. Over the 12 months to June 30, 2026: revenue $30.3M, net loss $31.2M.
- Cash flow
- In fiscal 2025 operations used $17.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Verrica Pharmaceuticals Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Verrica Pharmaceuticals Inc. does
Verrica Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRCA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $35.6M | -$17.9M | -$1.68 | -$17.6M |
| 2024 | $7.6M | -$76.6M | -$14.78 | -$61M |
| 2023 | $5.1M | -$67M | -$14.78 | -$38.9M |
| 2022 | $9M | -$24.5M | -$7.19 | -$19M |
| 2021 | $12M | -$35.1M | -$12.98 | -$28.5M |
| 2020 | n/a | -$42.7M | -$17.08 | -$31.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VRCA ranks in Health care
Latest SEC filings
What Verrica Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 54% to $5.9M versus the same quarter last year; diluted EPS -$0.62 versus $0.02.
- August 6, 2026
- June 9, 2026
- May 12, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 46% to $5M versus the same quarter last year; diluted EPS -$0.45 versus -$1.03.
- May 12, 2026
- April 20, 2026
- April 20, 2026Additional proxy material DEFA14A
- April 20, 2026Proxy statement DEF 14A
- March 11, 2026Annual report 10-K · period to December 31, 2025Revenue rose 370% to $35.6M versus the prior year; diluted EPS -$1.68 versus -$14.78.
Insider trades
What the people running Verrica Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $210.9K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | Kirby John J.Interim CFO | Bought | 5,000 | $24.7K |
| August 18, 2026 | Rosenberg Noah L.CMO | Bought | 2,030 | $10K |
| August 17, 2026 | Rosenberg Noah L.CMO | Bought | 4,200 | $20.6K |
| August 17, 2026 | Rieger JaysonCEO and President, Director | Bought | 5,000 | $24.6K |
| August 17, 2026 | Zawitz DavidChief Operating Officer | Bought | 6,000 | $29.9K |
| August 14, 2026 | Rieger JaysonCEO and President, Director | Bought | 20,000 | $101.2K |
| December 23, 2025 | Kirby John J.Interim CFO | Received as pay | 10,000 | - |
| November 25, 2025 | Manning Paul BDirector, 10% owner | Bought | 1,375,380 | $5.8M |
Who owns VRCA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Paul B Manning13D, may seek influence with 2 related filers | 49.9% | November 28, 2025 |
| Caligan Partners LP13D, may seek influence with 1 related filers | 9.99% | December 30, 2025 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 5.5% | January 29, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 7,573,703 shares in total, about $27.2M at the last price.
| Holder | Shares |
|---|---|
| Manning Paul BDirector, 10% owner | 7,306,5613,348,372 held indirectly |
| Rieger JaysonCEO and President, Director | 207,593 |
| Zawitz DavidChief Operating Officer | 27,000 |
| Kirby John J.Interim CFO | 23,962 |
| Rosenberg Noah L.CMO | 8,587 |
Questions about VRCA
What does Verrica Pharmaceuticals Inc. do?
Verrica Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as VRCA. Its shares trade on NASDAQ under the ticker VRCA.
What is Verrica Pharmaceuticals Inc.'s net worth?
Verrica Pharmaceuticals Inc. has a market value (market cap) of $61.7M at the latest share price, and shareholders' equity of $4.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Verrica Pharmaceuticals Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $31.2M on revenue of $30.3M.
How much revenue does Verrica Pharmaceuticals Inc. make?
Over the twelve months to June 30, 2026 Verrica Pharmaceuticals Inc. reported revenue of $30.3M. That is 106.2% more than a year earlier.
When did Verrica Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
When is Verrica Pharmaceuticals Inc.'s next earnings report?
Verrica Pharmaceuticals Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VRCA with
Follow VRCA
Get an email when Verrica Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Verrica Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.